

Hanneke Schuitemaker

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1707312/hanneke-schuitemaker-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80
papers

6,212
citations

32
h-index

78
g-index

112
ext. papers

8,884
ext. citations

17.2
avg, IF

5.69
L-index

#	Paper	IF	Citations
80	Passive transfer of Ad26.COVS2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.. <i>Npj Vaccines</i> , 2022 , 7, 2	9.5	0
79	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COVS2.S.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	8
78	Durability and expansion of neutralizing antibody breadth following Ad26.COVS2.S vaccination of mice.. <i>Npj Vaccines</i> , 2022 , 7, 23	9.5	2
77	Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6 cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.. <i>Human Vaccines and Immunotherapeutics</i> , 2022 , 1-11	4.4	1
76	A homologous or variant booster vaccine after Ad26.COVS2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.. <i>Science Translational Medicine</i> , 2022 , eabm4996	17.5	1
75	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.. <i>Npj Vaccines</i> , 2022 , 7, 53	9.5	0
74	The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization. <i>Journal of Virology</i> , 2021 , JVI0155221	6.6	2
73	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COVS2.S vaccination predict durable protection in rhesus macaques. <i>Nature Communications</i> , 2021 , 12, 5877	17.4	9
72	Ad26.COVS2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. <i>Npj Vaccines</i> , 2021 , 6, 39	9.5	21
71	Immunogenicity of the Ad26.COVS2.S Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1535-1544	27.4	139
70	Immunogenicity and efficacy of one and two doses of Ad26.COVS2.S COVID vaccine in adult and aged NHP. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	25
69	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. <i>Annals of Internal Medicine</i> , 2021 , 174, 585-594	8	14
68	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection. <i>Journal of Virology</i> , 2021 ,	6.6	14
67	Interim Results of a Phase 1-2a Trial of Ad26.COVS2.S Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021 , 384, 1824-1835	59.2	575
66	Protective efficacy of Ad26.COVS2.S against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021 , 596, 423-427	50.4	22
65	Safety and Efficacy of Single-Dose Ad26.COVS2.S Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021 , 384, 2187-2201	59.2	865
64	Immunogenicity of Ad26.COVS2.S vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021 , 596, 268-272	50.4	122

63	Low-dose Ad26.COVS protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021 , 184, 3467-3473.e11	56.2	23
62	Durable Humoral and Cellular Immune Responses Following Ad26.COVS Vaccination for COVID-19 2021 ,		10
61	Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2021 , 39, 3081-3101	4.1	28
60	Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6 cell-line: a phase 1 randomized controlled trial in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 1366-1373	4.4	2
59	Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. <i>Journal of Infectious Diseases</i> , 2021 , 223, 699-708	7	18
58	Immunity elicited by natural infection or Ad26.COVS vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021 , 13, eabj3789	17.5	13
57	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVS Vaccination. <i>New England Journal of Medicine</i> , 2021 , 385, 951-953	59.2	77
56	Low-Dose Ad26.COVS Protection Against SARS-CoV-2 Challenge in Rhesus Macaques 2021 ,		8
55	Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. <i>Npj Vaccines</i> , 2020 , 5, 49	9.5	9
54	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020 , 26, 498-501	50.5	17
53	Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. <i>Npj Vaccines</i> , 2020 , 5, 112	9.5	9
52	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	99
51	Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. <i>Npj Vaccines</i> , 2020 , 5, 91	9.5	153
50	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020 , 586, 583-588	50.4	550
49	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , 2020 , 26, 1694-1700	50.5	176
48	Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged 18-60 Years. <i>Journal of Infectious Diseases</i> , 2020 , 222, 979-988	7	33
47	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	15
46	Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. <i>Viruses</i> , 2019 , 11,	6.2	3

45	Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations. <i>Npj Vaccines</i> , 2019 , 4, 54	9.5	19
44	A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2018 , 23, 584-595	10.6	55
43	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018 , 392, 232-243	40	170
42	A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. <i>PLoS ONE</i> , 2018 , 13, e0192312	3.7	30
41	An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6 \square cell culture platform is immunogenic and safe in a non-human primate model. <i>Vaccine</i> , 2018 , 36, 6979-6987	4.1	6
40	Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform. <i>PLoS ONE</i> , 2017 , 12, e0174728	3.7	9
39	HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. <i>Retrovirology</i> , 2016 , 13, 48	3.6	17
38	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016 , 540, 284-287	50.4	183
37	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. <i>Nature Microbiology</i> , 2016 , 2, 16199	26.6	103
36	The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 1135-1142	1.6	10
35	Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1610-23	27.4	189
34	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , 2015 , 349, 320-4	33.3	236
33	A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. <i>Nature Communications</i> , 2015 , 6, 8143	17.4	174
32	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015 , 163, 988-98	56.2	230
31	Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. <i>Vaccine</i> , 2015 , 33, 5406-5414	4.1	38
30	Identification of Genes Whose Expression Profile Is Associated with Non-Progression towards AIDS Using eQTLs. <i>PLoS ONE</i> , 2015 , 10, e0136989	3.7	7
29	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. <i>PLoS Pathogens</i> , 2015 , 11, e1005110	7.6	61
28	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. <i>Cell</i> , 2015 , 163, 1702-15	56.2	251

27	Production of high titer attenuated poliovirus strains on the serum-free PER.C6() cell culture platform for the generation of safe and affordable next generation IPV. <i>Vaccine</i> , 2015 , 33, 6611-6	4.1	11
26	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. <i>Lancet HIV,the</i> , 2014 , 1, e41-8	7.8	8
25	Low level of HIV-1 evolution after transmission from mother to child. <i>Scientific Reports</i> , 2014 , 4, 5079	4.9	6
24	Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. <i>Aids</i> , 2014 , 28, 1237-40	3.5	18
23	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. <i>Retrovirology</i> , 2013 , 10, 102	3.6	37
22	Gag sequence variation in a human immunodeficiency virus type 1 transmission cluster influences viral replication fitness. <i>Journal of General Virology</i> , 2013 , 94, 354-359	4.9	1
21	PER.C6() cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. <i>Vaccine</i> , 2013 , 31, 850-6	4.1	33
20	Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals. <i>PLoS ONE</i> , 2013 , 8, e54684	3.7	20
19	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. <i>Nature</i> , 2012 , 482, 89-93	50.4	391
18	Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. <i>PLoS ONE</i> , 2012 , 7, e44115	3.7	41
17	Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. <i>Journal of Virology</i> , 2012 , 86, 2045-55	6.6	49
16	Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1045-53	7	128
15	Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. <i>Aids</i> , 2009 , 23, 2405-14	3.5	82
14	Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. <i>Aids</i> , 2009 , 23, 19-28	3.5	72
13	Sensitivity of Primary R5 HIV-1 to Inhibition by Rantes Correlates with Sensitivity to Small-Molecule R5 Inhibitors. <i>Antiviral Therapy</i> , 2005 , 10, 231-237	1.6	9
12	T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. <i>Nature Immunology</i> , 2000 , 1, 285-9	19.1	311
11	Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment. <i>BioDrugs</i> , 1997 , 8, 243-9	7.9	
10	Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. <i>Clinical Infectious Diseases</i> , 1995 , 21, 556-60	11.6	52

9	Recent development on research in AIDS pathogenesis. <i>Vox Sanguinis</i> , 1994 , 67 Suppl 3, 133-6	3.1	1
8	Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis?. <i>Journal of Leukocyte Biology</i> , 1994 , 56, 218-24	6.5	38
7	Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses		4
6	Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COVS COVID-19 vaccine candidate in adult and aged rhesus macaques		6
5	Neutralizing antibodies elicited by the Ad26.COVS COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.		7
4	Ad26.COVS elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern		17
3	Ad26.COVS-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing		2
2	Durability of antibody responses elicited by a single dose of Ad26.COVS and substantial increase following late boosting		9
1	SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COVS predict durable protection in rhesus macaques		2